Tocilizumab reduces hypercoagulation in COVID-19 – Perspectives from the coagulation and immunomodulation Covid assessment (Coag-ImmCovA) clinical trial
Tocilizumab reduces hypercoagulation in COVID-19 – Perspectives from the coagulation…
Ler MaisTocilizumab reduces hypercoagulation in COVID-19 – Perspectives from the coagulation…
Ler MaisAnti-platelet factor 4 immunothrombotic syndromes Richard J. Buka 1), Sue…
Ler MaisAging-related alterations in mechanistic target of rapamycin signaling promote platelet…
Ler MaisBeing John Plasma Volumovich, pecularities of plasma volume estimation in…
Ler MaisObese patients with atrial fibrillation are more efficiently protected from…
Ler MaisLow recurrent thrombosis rates in single positive antiphospholipid syndrome regardless…
Ler MaisRisk of thrombosis, hemorrhage and leukemic transformation in patients with…
Ler MaisImpact of allele-selective silencing of von Willebrand factor in mice…
Ler MaisAnticoagulation Management in V-V ECMO Patients: A Multidisciplinary Pragmatic Protocol…
Ler MaisTestes Viscoelásticos na Avaliação de Alterações da Hemostase na Infeção…
Ler Mais